As of May 2021, 16% of pregnant people identified in CDC's Vaccine Safety Datalink had received ≥1 dose of a COVID-19 vaccine during pregnancy in the U.S. Vaccination was lowest among Hispanic people (12%), non-Hispanic Black people (6%), and people aged 18-24 years (6%), and highest among non-Hispanic Asian people (25%) and people aged 35-49 years (23%).
During the COVID-19 pandemic, emergency department (ED) visits for suspected suicide attempts increased among adolescents aged 12-17 years, especially girls. During February-March 2021, suspected suicide attempt ED visits were 51% higher among girls aged 12-17 years than during 2019; among boys aged 12-17 years, suspected suicide attempt ED visits increased 4%.
By May 2021, 69%, 45%, and 26% of adults aged ≥65, 50-64, and 18-49 years were fully vaccinated. From November-December 2020 to April-May 2021, the rate ratios of COVID-19 incidence, emergency department visits, hospital admissions, and deaths among persons aged ≥65 (≥70 for hospitalizations) to persons aged 18-49 years declined 40%, 59%, 65%, and 66% respectively.
COVID-19 adolescent hospitalization rates peaked at 2.1 per 100,000 in early January 2021, declined to 0.6 in mid-March, and rose to 1.3 in April. Among hospitalized adolescents, nearly one-third required intensive care unit admission and 5% required invasive mechanical ventilation, but no associated deaths occurred.
Based on the national trend in ESRD deaths during the first 7 months of the U.S. COVID-19 pandemic (February-August 2020), an estimated 8.7-12.9 excess deaths per 1,000 patients or 6,953-10,316 excess deaths in a population of 798,611 U.S. ESRD patients occurred.
Disparities in county-level vaccination coverage by social vulnerability have increased as vaccine eligibility has expanded. By May 2021, vaccination coverage was lower among adults living in counties with low socioeconomic status and higher percentages of households with children, single parents, and people with disabilities.
This report describes how Sub-Saharan African countries have overcome challenges to initiate and scale up HIV viral load testing to monitor patients receiving Antiretroviral therapy.
As of April 30, 2021, approximately 101 million people in the U.S. had been fully vaccinated against COVID-19. Almost 10,300 COVID-19 vaccine breakthrough infections were reported from 46 states and territories. Vaccine breakthrough infections occur in only a small fraction of all vaccinated people.
Utah implemented two high school COVID-19 testing programs to sustain in-person instruction and extracurricular activities. During November 30, 2020-March 20, 2021, among 59,552 students who received testing, 1,886 (3.2%) had a positive result. These programs facilitated the completion of approximately 95% of high school athletic events and saved an estimated 109,752 in-person instruction student-days.
COVID-19 incidence was 37% lower in schools that required teachers and staff to use masks and 39% lower in schools that improved ventilation. Ventilation strategies associated with lower school incidence included dilution methods alone (35% lower incidence) or in combination with filtration methods (48% lower incidence).
The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna COVID-19 vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective.
In May 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19.
After the first 3.5 months of the U.S. COVID-19 vaccination program, 79.1% of adults aged ≥65 years had received ≥1 dose, with higher vaccination initiation among men. Counties with lower vaccination initiation rates had higher percentages of older adults with social vulnerabilities.
Data from six models indicate that with high vaccination coverage and moderate nonpharmaceutical intervention (NPI) adherence, hospitalizations and deaths will likely remain low nationally, with a sharp decline in cases projected by July 2021. Lower NPI adherence could lead to substantial increases in severe COVID-19 outcomes, even with improved vaccination coverage
The NYC Department of Health and Mental Hygiene analyzed laboratory and epidemiologic data to characterize cases of B.1.526 infection and the associated potential for breakthrough infection and reinfection. Preliminary evidence suggests that, to date, B.1.526 does not lead to more severe disease or increased risk for infection after vaccination.
On January 24, the Colorado Department of Public Health and Environment (CDPHE) identified the first Colorado case of COVID-19 attributed to the B.1.427 and B.1.429 variants. To improve convenience sampling to identify and track emerging variants, CDPHE established a 30-site statewide sentinel surveillance system.
Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019-20) were 8.2 and 0.05 per 100,000 doses, respectively.
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events.